drugset / Trial / NCT00055471
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
Treatment
Summary
The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer
Timeline
- Start
- 2003-06
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zibotentan | Small molecule | 10 mg | Oral |
| Subject | Zibotentan | Small molecule | 15 mg | Oral |
| Subject | Zibotentan | Small molecule | 22.5 mg | Oral |